Treatment of individuals exhibiting defective CD40L
US6106832A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 22, 1996 |
| Grant date | Aug 22, 2000 |
| Priority date | — |
| Expiry date | Jan 22, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating individuals exhibiting a defective CD40 ligand gene (i.e., X-linked hyper IgM patients and certain individuals afflicted with combined variable immunodeficiency) are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.